WO2022265053A1 - 育毛剤 - Google Patents

育毛剤 Download PDF

Info

Publication number
WO2022265053A1
WO2022265053A1 PCT/JP2022/024019 JP2022024019W WO2022265053A1 WO 2022265053 A1 WO2022265053 A1 WO 2022265053A1 JP 2022024019 W JP2022024019 W JP 2022024019W WO 2022265053 A1 WO2022265053 A1 WO 2022265053A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
phytosphingosine
minoxidil
growth
hair restorer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/024019
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
秀樹 高橋
荘太 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjuvant Holdings Co Ltd
Original Assignee
Adjuvant Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvant Holdings Co Ltd filed Critical Adjuvant Holdings Co Ltd
Priority to US18/571,559 priority Critical patent/US20240285502A1/en
Priority to CN202280055000.4A priority patent/CN117881387A/zh
Priority to JP2023530385A priority patent/JPWO2022265053A1/ja
Priority to KR1020247001998A priority patent/KR20240023617A/ko
Priority to TW111122675A priority patent/TW202317077A/zh
Publication of WO2022265053A1 publication Critical patent/WO2022265053A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596

Definitions

  • the present invention relates to a hair restorer. More particularly, it relates to a hair restorer containing phytosphingosine and minoxidil.
  • Hair growth repeats growth and shedding according to a hair cycle (hair cycle) consisting of a growth phase, a regression phase, and a resting phase.
  • the symptoms of androgenetic alopecia are that the balance of the hair cycle is lost due to some cause, the period of growth period is shortened, the proportion of telogen hair is increased, and the hair becomes vellus (downy hair).
  • Histologically it has been reported that the size of anagen hair follicles is smaller than that of healthy scalp, the development of dermal papilla is poor, and the capillary network surrounding hair follicles is reduced (Non-Patent Document 1).
  • hair restorers that improve hair growth and hair type/hair quality.
  • active ingredients that contribute to the regulation of the hair cycle, which is the life cycle of hair, have been proposed and are being marketed as hair restorers.
  • VEGF Vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • Phytosphingosine is known as a component of cosmetic raw materials (see Patent Document 4). However, there is no report on the hair growth effect of phytosphingosine.
  • An object of the present invention is to provide a hair restorer having an excellent hair growth effect.
  • the present inventors have made intensive studies to solve the above problems, and found that the use of phytosphingosine as an active ingredient can exhibit hair growth activity, and the use of phytosphingosine and minoxidil as active ingredients. As a result, the inventors have found that strong hair growth activity can be exhibited, and have completed the present invention.
  • the first means of the present invention for solving the above problems is a hair restorer characterized by containing phytosphingosine and minoxidil as active ingredients.
  • the second means of the present invention for solving the above problems is a hair restorer for combined use with minoxidil, characterized by containing phytosphingosine as an active ingredient.
  • a third means of the present invention for solving the above problems is a hair restorer for combined use with phytosphingosine, characterized by containing minoxidil as an active ingredient.
  • the fourth means of the present invention for solving the above problems is the hair restorer according to any one of the first to third means of the present invention, which is used for promoting hair shaft growth or hair growth. is.
  • a fifth means of the present invention for solving the above-mentioned problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving hair shaft elongation speed. is.
  • the sixth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for improving the maximum length of hair shafts. is.
  • the seventh means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the diameter of the hair shaft. be.
  • the eighth means of the present invention for solving the above problems is the hair restorer according to any one of the first to fourth means of the present invention, which is used for increasing the number of hairs. .
  • the ninth means of the present invention for solving the above problems is the hair restorer according to any one of the first to eighth means of the present invention, which is a solution.
  • a tenth means of the present invention for solving the above problems is the hair restorer according to any one of the first to ninth means of the present invention for hair, bristles, eyebrows and/or eyelashes. is an agent.
  • the eleventh means of the present invention for solving the above problems is a method for producing a hair restorer, characterized by having a step of incorporating phytosphingosine and minoxidil as active ingredients into a formulation.
  • the twelfth means of the present invention for solving the above problems is a method for producing a hair restorer for combined use with minoxidil, characterized by including a step of incorporating phytosphingosine as an active ingredient into the formulation.
  • the thirteenth means of the present invention for solving the above problems is a method for producing a hair restorer for combined use with phytosphingosine, characterized by including a step of incorporating minoxidil as an active ingredient into the formulation.
  • a fourteenth means of the present invention for solving the above problems is a hair restorer kit containing a preparation containing phytosphingosine and a preparation containing minoxidil.
  • a fifteenth means of the present invention for solving the above problems is a hair restorer kit for combined use with minoxidil, which contains a formulation containing phytosphingosine.
  • the sixteenth means of the present invention for solving the above problems is a hair restorer kit for combined use with phytosphingosine, which contains a formulation containing minoxidil.
  • the seventeenth means of the present invention for solving the above problems is a hair growth method characterized by administering phytosphingosine and minoxidil as active ingredients.
  • An eighteenth means of the present invention for solving the above problems is a hair restoration method comprising administering the hair restorer according to any one of the first to tenth means of the present invention to a subject. .
  • Another means of the present invention for solving the above problems is a scalp care agent containing phytosphingosine and minoxidil as active ingredients.
  • Another means of the present invention for solving the above problems is a method for improving scalp symptoms including administering to a subject a scalp care agent containing phytosphingosine and minoxidil as active ingredients.
  • VEGF production promoter for dermal papilla cells containing phytosphingosine and minoxidil as active ingredients.
  • phytosphingosine and minoxidil are contained or used in combination as active ingredients in a hair restorer, which is an external preparation, to promote hair shaft growth in hair such as head hair, pubic hair, eyebrows and/or eyelashes.
  • a hair restorer which is an external preparation, to promote hair shaft growth in hair such as head hair, pubic hair, eyebrows and/or eyelashes.
  • FIG. 1 is a graph showing changes in VEGF gene expression levels in human dermal papilla cells stimulated with minoxidil, phytosphingosine, and phytosphingosine and minoxidil for 72 hours.
  • the active ingredients of the hair restorer and scalp care agent according to the present invention contain both phytosphingosine and minoxidil, or contain phytosphingosine and minoxidil in combination.
  • the concentration of phytosphingosine and minoxidil, which are active ingredients in the hair restorer and scalp care agent of the present invention is 0.001 to 20% by weight relative to the total hair restorer and scalp care agent. More specifically, it is 0.005 to 10% by weight.
  • the hair restorer and scalp care agent of the present invention are pharmaceuticals, quasi-drugs, cosmetics including cosmetics for hair, lashes, eyebrows and/or eyelashes, and cosmetics for the scalp, and ointments, cataplasms, liniments, lotions, and liquids for external use. , dusting agents, creams, gels, milky lotions, hair tonics, hair sprays, microneedles, etc., and can be used as preparations having various dosage forms such as, but not limited to, these.
  • the hair restorer and scalp care agent of the present invention can be produced through a process of incorporating phytosphingosine and minoxidil as active ingredients.
  • the hair restorer and scalp care agent for combined use with minoxidil of the present invention are obtained by going through a step of incorporating phytosphingosine as an active ingredient, and the hair restorer and scalp care agent for combined use with phytosphingosine are , minoxidil as an active ingredient.
  • a step of adding additives for formulation may be added.
  • the dosage forms of these preparations are the same but are a combination of different dosage forms. It can also be provided as a kit for providing formulations of those dosage forms.
  • Components of these additives include, for example, excipients, stabilizers, flavoring agents, bases, dispersants, diluents, anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants, Active agents, anionic polymers, nonionic polymers, ethylene oxide/propylene oxide block copolymers, alcohols, emulsifiers, percutaneous absorption enhancers, pH adjusters, preservatives, coloring agents, oils and fats, mineral oils, etc.
  • the hair restorer and scalp care agent of the present invention may further contain known ingredients having effects such as hair growth, hair restoration, and hair nourishing.
  • the dosage of the active ingredient per administration of the hair restorer and scalp care agent in the means of the present invention can be adjusted so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the dosage can be, for example, 0.005 to 200 mg, specifically 0.05 to 100 mg, and more specifically 0.5 to 10 mg.
  • the administration frequency of the hair restorer and scalp care agent of the present invention can be once or multiple times so that the effects of the hair restorer and scalp care agent of the present invention are exhibited.
  • the frequency of administration of the hair restorer and scalp care agent of the present invention can be, for example, 1 to 6 times per day. Specifically, it can be 1 to 3 times per day, more specifically 1 to 2 times per day.
  • the hair restorer and scalp care agent of the present invention relate to promotion of hair shaft growth, hair growth and prevention of hair loss, preferably promotion of hair shaft growth and hair growth.
  • promoting hair shaft growth means improving the hair shaft elongation speed, improving the maximum hair shaft length, and/or increasing the hair shaft diameter.
  • hair growth means that hair growth has stopped at a site where hair does not grow (the hair shaft does not protrude from the epidermis) or where the number of hairs is small, or the ability to grow hair is reduced. It means to promote the growth of new hairs from the pores to increase the number of hairs, in particular, to shorten the resting phase in the hair cycle and / or to restart the stopped hair cycle. .
  • having a hair shaft growth promoting effect means acting favorably on hair shaft growth promotion, and the property showing the hair shaft growth promoting effect is referred to as “hair shaft growth promoting activity”.
  • has a hair growth effect means that it acts favorably on hair growth, and the property showing the hair growth effect is referred to as “hair growth promoting activity”.
  • hair loss refers to a phenomenon in which hair shafts fall out of pores, and specifically refers to an increase in inhibitory cytokines that inhibit cell proliferation and cell death. Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • anti-hair loss activity Attributes that demonstrate anti-hair loss efficacy are referred to as "anti-hair loss activity.”
  • the term “has an anti-hair loss effect” means that the number of hair shafts falling out from pores is reduced through the inhibition or reduction of inhibitory cytokines and the suppression of cell death. It is a physiological phenomenon that is different from the attribute that indicates the hair effect.
  • scalingp symptoms means symptoms such as dandruff, rough skin, dry scalp, erythema, itching, and pimples.
  • scaling symptom improvement means suppression or improvement of dandruff, rough skin, dryness of the scalp, erythema, itching, pimples, and the like.
  • the hair restorer of the present invention can be used to improve the elongation speed of hair shafts or the maximum length of hair shafts. Then, the hair shaft elongation speed can be improved, for example, by about 110% at maximum, and specifically by about 25 to 110%, compared to the hair shaft elongation speed in the standard data of the hair cycle. More specifically, it can be improved by about 33 to 110%.
  • the maximum length of the hair shaft can be improved, for example, by about 49% at maximum, specifically by about 1 to 49%, compared to the maximum length of the hair shaft in the standard data of the hair cycle. More specifically, it can be improved by about 2 to 49%.
  • the hair restorer of the present invention can be used to increase the diameter of hair shafts.
  • the hair restorer of the present invention causes new hairs to grow from pores where hair growth has stopped (no hair shafts protrude from the epidermis) or where there are few hairs, or where hair growth ability has decreased. It can be used to promote hair growth to increase hair number, and in particular can be used to shorten the telogen phase in the hair cycle and/or to restart stopped hair cycles.
  • the hair restorer and scalp care agent of the present invention can be used not only for humans but also for animals such as livestock and pets.
  • a hair growth method and a scalp symptom amelioration method comprising administering an external preparation containing phytosphingosine and minoxidil to subjects including humans and non-human animals such as livestock and pets. be.
  • the VEGF gene is expressed in dermal papilla cells and exhibits effects such as promotion of hair shaft growth, improvement in hair shaft elongation speed, improvement in maximum hair shaft length, and increase in hair shaft diameter in head hair, bristles, eyebrows and/or eyelashes. is said to contribute to Therefore, human dermal papilla cells were used to evaluate the enhancement of VEGF gene expression in each component.
  • Human dermal papilla cells and medium Human dermal papilla cells (catalog number: CA60205a, Caucasian, 29-year-old male, Toyobo Co., Ltd. (Japan)) were purchased and prepared as described in the protocol. We maintained and cultured the cells and performed test evaluations.
  • the FastGene RNA Basic Kit (catalog number: FG-80250, Nippon Genetics Co., Ltd. (Japan)) was used to collect total RNA from the cells.
  • 300 ⁇ L of lysis buffer RL was added per well, and the cells were lysed by pipetting. 300 ⁇ L of 70% ethanol was added to the cell lysate and mixed by pipetting. The sample solution was added to the FastGene RNA binding column and centrifuged at 10000 rpm for 1 minute at room temperature. After discarding the filtrate that passed through the column from the collection tube and returning the FastGene RNA binding column to the original collection tube, 600 ⁇ L of washing buffer RW1 was added to the FastGene RNA binding column and centrifuged at 10000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 700 ⁇ L of washing buffer RW2 was added to the FastGene RNA binding column, and centrifuged at 10000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube, set, and centrifuged at 15000 rpm for 1 minute at room temperature.
  • the FastGene RNA binding column was transferred to a new collection tube and set, 50 ⁇ L of elution buffer RE was added to the center of the membrane of the FastGene RNA binding column, and centrifuged at 10000 rpm for 1 minute at room temperature to collect the purified RNA.
  • the concentration of the collected RNA was measured with NanoDrop Lite (catalog number: ND-LITE, Thermo Fisher Scientific Co., Ltd.) and stored at -80°C until the next cDNA conversion.
  • FastGene scriptase II cDNA synthesis 5x Ready Mix (catalog number: NE-LS64, Nippon Genetics Co., Ltd. (Japan)) was used for cDNA synthesis.
  • the total RNA produced in a new tube was diluted with RNase-Free Water so that the concentration was 20 ng/mL, and 4 ⁇ L of FastGene scriptase II cDNA synthesis 5 ⁇ Ready Mix was added to 16 ⁇ L of this sample solution and vortexed.
  • a MiniAmp thermal cycler Thermo Fisher Scientific Co., Ltd.
  • the cDNA synthesized by the above method was used for real-time PCR.
  • Add each cDNA template dilution to a predetermined well of a 96-well plate, add THUNDERBIRD SYBR qPCR Mix (catalog number: QPS-201, Toyobo Co., Ltd. (Japan)) and primers, mix, and mix with QuantStudio 7 Flex Real - Gene expression was analyzed with Time PCR System (catalog number: 4485693, Thermo Fisher Scientific Co., Ltd.).
  • As a PCR reaction 40 cycles of 95°C for 5 seconds, 60°C for 30 seconds, and 72°C for 30 seconds were performed.
  • VEGF gene-specific primers used in the test and the GAPDH gene-specific primers used as internal standards are shown below.
  • Primer for detecting VEGF gene expression Forward direction: aggccagcacataggagaga (SEQ ID NO: 1) Reverse: acgcgagtctgtgttttgc (SEQ ID NO: 2)
  • Primer for detecting GAPDH gene expression Forward direction: catccctgcctctactggcgctgcc (SEQ ID NO: 3)
  • the relative expression level of each gene was calculated as follows.
  • the Ct value (PCR cycle number) was calculated from the intersection of the amplification curve of each gene and the threshold line.
  • the value obtained by dividing the Ct value of the target gene by the Ct value of the internal standard GAPDH gene is the relative expression level.
  • phytosphingosine enhances the expression of the VEGF gene in dermal papilla cells, promotes hair shaft growth in hairs such as scalp hair, bristles, eyebrows and/or eyelashes, improves hair shaft elongation speed, and increases the maximum hair shaft length. It was confirmed that it is useful as an active ingredient of a hair restorer and a scalp care agent that have the effect of improving the hair shaft diameter and increasing the diameter of the hair shaft. Furthermore, when phytosphingosine and minoxidil are used in combination, the expression of the VEGF gene in dermal papilla cells is significantly and markedly enhanced compared to when phytosphingosine or minoxidil is used alone as an active ingredient.
  • a hair restorer containing both phytosphingosine and minoxidil, or a combination of phytosphingosine and minoxidil, as active ingredients can be used to restore hair, bristles, eyebrows and/or eyelashes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2022/024019 2021-06-19 2022-06-15 育毛剤 Ceased WO2022265053A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US18/571,559 US20240285502A1 (en) 2021-06-19 2022-06-15 Hair growth agent
CN202280055000.4A CN117881387A (zh) 2021-06-19 2022-06-15 育毛剂
JP2023530385A JPWO2022265053A1 (https=) 2021-06-19 2022-06-15
KR1020247001998A KR20240023617A (ko) 2021-06-19 2022-06-15 육모제
TW111122675A TW202317077A (zh) 2021-06-19 2022-06-17 育毛劑

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021102088 2021-06-19
JP2021-102088 2021-06-19

Publications (1)

Publication Number Publication Date
WO2022265053A1 true WO2022265053A1 (ja) 2022-12-22

Family

ID=84527114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/024019 Ceased WO2022265053A1 (ja) 2021-06-19 2022-06-15 育毛剤

Country Status (6)

Country Link
US (1) US20240285502A1 (https=)
JP (1) JPWO2022265053A1 (https=)
KR (1) KR20240023617A (https=)
CN (1) CN117881387A (https=)
TW (1) TW202317077A (https=)
WO (1) WO2022265053A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025084438A1 (ja) * 2023-10-21 2025-04-24 株式会社アジュバンホールディングス 硫酸転移酵素産生促進剤および硫酸転移酵素活性促進剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240023618A (ko) * 2021-06-19 2024-02-22 가부시키가이샤 아쥬반트 홀딩스 육모제

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0525023A (ja) * 1991-07-18 1993-02-02 Pola Chem Ind Inc 養毛料
JPH09241156A (ja) * 1996-03-06 1997-09-16 Noevir Co Ltd 血流促進剤及びこれを配合して成る皮膚外用剤
JP2016520546A (ja) * 2013-04-04 2016-07-14 ピトス カンパニー リミテッド 新規なフィトスフィンゴシン−１−リン酸誘導体、その調製方法、およびそれを含む脱毛の予防、治療、または育毛用組成物
CN106075390A (zh) * 2016-07-28 2016-11-09 广东药科大学 一种带正电荷的防脱复合柔性脂质体及其制备方法
KR20170114317A (ko) * 2016-04-04 2017-10-16 (주) 셀티스바이오 파이토스핑고신과 효모추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물
WO2022107866A1 (ja) * 2020-11-19 2022-05-27 株式会社アジュバンホールディングス 育毛剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
JPS63145217A (ja) 1986-12-09 1988-06-17 Taisho Pharmaceut Co Ltd 経皮投与組成物
JPS63150211A (ja) 1986-12-15 1988-06-22 Taisho Pharmaceut Co Ltd ミノキシジル配合外用剤
FR2714829B1 (fr) * 1994-01-10 1996-02-02 Oreal Composition cosmétique et/ou dermatologique pour le traitement du vieillissement contenant des céramides, son utilisation.
JP3220434B2 (ja) 1998-12-28 2001-10-22 花王株式会社 化粧料
KR102099087B1 (ko) * 2018-09-04 2020-05-15 곽민재 탈모방지 또는 발모개선용 조성물
KR20200129009A (ko) * 2019-05-07 2020-11-17 주식회사 닥터스칼프 피토스핑고신을 이용한 두피 재생 및 모발성장을 촉진하는 화장품

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0525023A (ja) * 1991-07-18 1993-02-02 Pola Chem Ind Inc 養毛料
JPH09241156A (ja) * 1996-03-06 1997-09-16 Noevir Co Ltd 血流促進剤及びこれを配合して成る皮膚外用剤
JP2016520546A (ja) * 2013-04-04 2016-07-14 ピトス カンパニー リミテッド 新規なフィトスフィンゴシン−１−リン酸誘導体、その調製方法、およびそれを含む脱毛の予防、治療、または育毛用組成物
KR20170114317A (ko) * 2016-04-04 2017-10-16 (주) 셀티스바이오 파이토스핑고신과 효모추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물
CN106075390A (zh) * 2016-07-28 2016-11-09 广东药科大学 一种带正电荷的防脱复合柔性脂质体及其制备方法
WO2022107866A1 (ja) * 2020-11-19 2022-05-27 株式会社アジュバンホールディングス 育毛剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025084438A1 (ja) * 2023-10-21 2025-04-24 株式会社アジュバンホールディングス 硫酸転移酵素産生促進剤および硫酸転移酵素活性促進剤

Also Published As

Publication number Publication date
US20240285502A1 (en) 2024-08-29
CN117881387A (zh) 2024-04-12
TW202317077A (zh) 2023-05-01
JPWO2022265053A1 (https=) 2022-12-22
KR20240023617A (ko) 2024-02-22

Similar Documents

Publication Publication Date Title
JP4195763B2 (ja) 毛髪保護作用と毛髪減損の予防性並びにアンドロゲン性脱毛症の外因作用とその結果もたらされる毛髪減損の低下性において、改善された性質を有するヘアローション
EP2883549B1 (en) Antimicrobial composition comprising filobasidium-suppressing agent derived from natural substance
WO2019166089A1 (en) Dermatological product
WO2022265053A1 (ja) 育毛剤
EP2119431B1 (fr) Composition contenant l'association de madécassoside et/ou de terminoloside et d'une arginine et/ou l'un de ses sels et/ou l'un de ses dérivés; utilisation de l'association pour induire et/ou stimuler la croissance de ces fibres kératiniques humaines et/ou freiner leur chute.
WO2022265054A1 (ja) 育毛剤
WO2022265052A1 (ja) 育毛剤
WO2022181786A1 (ja) 育毛剤
FR2984129A1 (fr) Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu
WO2022181785A1 (ja) 育毛剤
JP7291333B2 (ja) 育毛剤
HK40102132A (zh) 育毛剂
HK40101945A (zh) 育毛剂
HK40092879A (zh) 育毛剂
JP2022551825A (ja) 皮膚微生物叢の多様性を増加させるためのｎ－メチルグリシンの新規化粧使用
HK40092880A (zh) 育毛剂
JP2004331664A (ja) ピリミジン−ｎ−オキシド誘導体を含有する毛髪用組成物、ケラチン繊維の成長を刺激し及び／又は抜毛を減少させるためのその使用
WO2025084438A1 (ja) 硫酸転移酵素産生促進剤および硫酸転移酵素活性促進剤
KR102817922B1 (ko) 피부장벽 강화용 조성물
JP2023025132A (ja) スカルプケア剤
JP3624318B2 (ja) 養毛剤
FR3156650A1 (fr) Composition cosmétique comprenant un composé apte à inhiber l’enzyme FIH-1 et un composé apte à inhiber l’enzyme PHD2 pour le traitement de la chute5 des cheveux
FR3156651A1 (fr) Composition cosmétique comprenant du niacinamide et un gingérol pour le traitement de la chute des cheveux
EP2465581B1 (en) Non-therapeutic use of a composition for promoting hair growth
WO2022124212A1 (ja) 毛髪改善のための組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22825041

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2023530385

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2301008231

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 18571559

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12023553452

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20247001998

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247001998

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202280055000.4

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 22825041

Country of ref document: EP

Kind code of ref document: A1